Physician profile
Allison Taylor
NPI 1639934425
$450.42
in general payments reported to CMS, 2019-2025
13 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $304 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $146.02 | 2025 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $45.60 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $44.72 | 2024 | |
| Merck Sharp & Dohme LLC | $39.88 | 2024 | Gardasil, Gardasil 9, Vaxelis |
| Novo Nordisk INC | $33.13 | 2024 | Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $23.56 | 2024 | Strensiq |
| Otsuka America Pharmaceutical, INC. | $23.34 | 2024 | Rexulti |
| Pfizer INC. | $16.66 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.37 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.33 | 2024 | Trulance, Xifaxan |
| Lilly USA, LLC | $16.14 | 2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $14.39 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.28 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.